Vanderbilt Network Lead Academic Participating Site for the NCTN

范德比尔特网络 (Vanderbilt Network) 主导 NCTN 学术参与网站

• 批准号: 10364747
• 负责人: JORDAN D BERLIN
• 金额: $ 50.76万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-07 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10364747
• 关键词: Academic Medical Centers; Advanced Malignant Neoplasm; Advisory Committees; Alabama; Antineoplastic Agents; Appointment; Area; Authorship; Automobile Driving; Award; Basic Science; Berlin; Biology; Breast; Budgets; Cancer Center; Cancer Patient; Catchment Area; Cessation of life; Clinical Cancer Center; Clinical Investigator; Clinical Research; Clinical Sciences; Clinical Trials; Clinical Trials Network; Collaborations; Collection; Communities; Compassion; Comprehensive Cancer Center; Conduct Clinical Trials; Country; Data; Death Rate; Department chair; Development; Diagnosis; Discipline; Discipline of obstetrics; Disease; Early Detection Research Network; Early Therapeutic-Clinical Trials Network; Eastern Cooperative Oncology Group; Education and Outreach; Enrollment; Ensure; Faculty; Funding; Goals; Grant; Growth; Gynecology; Health; Human; Image; Immunology; Immunotherapy; Incidence; Infection; Inflammation; Informatics; Infrastructure; Institutes; Institution; Institutional Review Boards; Jordan; Kentucky; Knowledge; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of pancreas; Manuscripts; Medical; Medicine; Mentors; Mentorship; Mission; Mutation; NCI Center for Cancer Research; National Cancer Institute; National Clinical Trials Network; Obesity; PD-1/PD-L1; PDL1 inhibitors; Patient-Centered Care; Patients; Phase II/III Clinical Trial; Physicians; Prevention; Prevention education; Principal Investigator; Process; Protocols documentation; Radiology Specialty; Research; Research Activity; Research Personnel; Research Priority; Research Support; Resource Sharing; Resources; Role; Science; Scientist; Services; Site; System; Technology; Tennessee; Time; Tobacco use; Training; Translational Research; Translations; United States; Universities; Work; cancer care; cancer clinical trial; cancer genomics; cancer therapy; data submission; design; drug discovery; early phase trial; evidence base; gastrointestinal; imaging science; improved; improved outcome; innovation; inter-institutional; interest; investigator-initiated trial; medical specialties; meetings; member; multidisciplinary; next generation; novel; patient oriented; programs; radiological imaging; recruit; resistance mechanism; success; targeted treatment; tumor; web site

PROJECT SUMMARY/ABSTRACT Vanderbilt-Ingram Cancer Center (VICC) is a matrix cancer center within Vanderbilt University Medical Center (VUMC). VICC has been part of the cooperative group system for over 27 years, and a Lead Academic Participating Site since the inception of the National Clinical Trials Network (NCTN). Throughout the years, we have integrated our physicians into leadership roles and our basic science into investigator-initiated trials, as well as enrolled patients onto clinical trials. Additionally, VICC has a long track record of leadership, both scientific and administrative, within the cooperative groups/NCTN, and helping junior faculty in clinical trial development. VICC brings great strengths to the NCTN, including two SPORE grants, an EDRN grant, a world class Institute of Imaging Science, eight highly funded scientific programs and an Early Therapeutics Clinical Trial Network (ETCTN) grant where successful early phase trials can be integrated into the NCTN. Our Personalized Cancer Medicine Initiative (PCMI) is dedicated to matching the appropriate therapy to the genetic changes, or mutations, that are driving the growth of cancers, with an active research component investigating mechanisms of resistance to targeted therapies. The key informatics of the VICC PCMI is MyCancerGenome, a website that not only informs physicians on the latest in cancer genomics, but also the availability of trials for patients whose tumors harbor actionable genetic alterations. With the development of PD-1/PD-L1 inhibitors and novel immune therapies on the horizon, VICC has recruited top researchers in immunology. Those top researchers in collaboration with other VUMC investigators created the Vanderbilt Institute for Infection, Immunology and Inflammation (VI4) with an overall mission to train the next generation scientists and physicians and make fundamental discoveries in the areas of infection biology, immunology and inflammation with the goal of increasing knowledge and improving human health. VICC clinicians and scientists are academic leaders in their respective disciplines and will continue to significantly contribute to the NCTN goals with the objective to improve the outcomes for cancer patients. The VICC selected Dr. Jordan Berlin, MD, as Principal Investigator to continue leading the efforts of the institution to integrate its scientific, academic and patient resources into the NCTN. He has been involved extensively in the cooperative groups/NCTN in conduct of clinical trials, mentorship and leadership. To assist Dr. Berlin with the conduct of this grant, VICC created two advisory boards, Internal Advisory Board (IAB) and NCTN Executive Committee (NEC), whose membership includes a broad representation of medical disciplines and disease interests across VICC and VUMC. The IAB assures the optimal use of the grant, such as budget review, assuring multidisciplinary involvement, and participation throughout the NCTN. The NEC implements operational functions, such as trial opening, accrual and mentoring. Operationally, the NEC has actively managed NCTN trial opening, accruals and participation across disciplines and groups. Both the IAB and NEC work to integrate VICC science into the NCTN. The VICC Clinical Trials Shared Resource and its NCTN team ensures that regulatory, biospecimen, radiology and data submissions are timely and highly accurate. An extensive plan to further advance the integration of the NCTN into the VICC clinical research enterprise and VICC research into the NCTN is detailed in the grant, including the new appointment of Dr. Berlin to the role of Associate Director for Clinical Research Strategy and Shared Resources. This is a new role for VICC, designed to allow coordination of clinical research priorities across all VICC programs and to increase the translation of VICC science into clinical trials. For this grant, Dr. Berlin’s new role will help to strengthen the prioritization of NCTN trials across the institution.

项目概要/摘要 范德比尔特-英格拉姆癌症中心 (VICC) 是范德比尔特大学医学中心内的矩阵癌症中心 (VUMC) 已成为合作团体系统的一部分超过 27 年，并且是领先的学术机构。 自国家临床试验网络 (NCTN) 成立以来，我们多年来一直在参与网站。 将我们的医生纳入领导角色，将我们的基础科学纳入研究者发起的试验，如 此外，VICC 在招募患者参加临床试验方面拥有长期的领先记录。 科学和行政，在合作小组/NCTN 内，并帮助初级教师进行临床试验 VICC 的发展为 NCTN 带来了巨大的优势，包括两项 SPORE 资助、一项 EDRN 资助、一项世界资助。 影像科学研究所、八个高额资助的科学项目和一个早期治疗临床 试验网络 (ETCTN) 资助，成功的早期试验可以整合到我们的 NCTN 中。 个性化癌症医学计划 (PCMI) 致力于将适当的治疗与遗传相匹配 正在推动癌症生长的变化或突变，积极的研究部分正在调查 VICC PCMI 的关键信息是 MyCancerGenome， 该网站不仅向医生通报癌症基因组学的最新信息，还向医生通报癌症试验的可用性 随着 PD-1/PD-L1 抑制剂的开发，肿瘤具有可操作的基因改变的患者。 和即将出现的新型免疫疗法，VICC 招募了免疫学领域的顶尖研究人员。 研究人员与其他 VUMC 研究人员合作创建了范德比尔特感染研究所， 免疫学和炎症（VI4）的总体使命是培训下一代科学家和 医生并在感染生物学、免疫学和炎症领域做出基础性发现 以增加知识和改善人类健康为目标。 各自学科的学术领袖，并将继续为 NCTN 的目标做出重大贡献 旨在改善癌症患者的治疗结果。 VICC 选择 Jordan Berlin 博士作为首席研究员，继续领导该项目的工作 机构将其科学、学术和患者资源整合到 NCTN。 一般在合作小组/NCTN 中进行临床试验、指导和领导。 Berlin 博士通过这笔拨款，VICC 创建了两个顾问委员会：内部顾问委员会 (IAB) 和 NCTN 执行委员会 (NEC)，其成员包括医学学科的广泛代表 IAB 确保拨款的最佳使用，例如预算。 审查，确保多学科参与以及整个 NCTN 的参与。 运营职能，例如审判开放、应计费用和指导。 管理 IAB 和 NEC 的 NCTN 试验开放、应计费用和跨学科和团体的参与。 致力于将 VICC 科学整合到 NCTN 中。VICC 临床试验共享资源及其 NCTN 团队。 确保监管、生物样本、放射学和数据提交及时且高度准确。 进一步推进 NCTN 与 VICC 临床研究企业整合的广泛计划 拨款中详细介绍了 VICC 对 NCTN 的研究，包括新任命 Berlin 博士担任 临床研究策略和共享资源副总监 这是 VICC 的新职位。 旨在协调所有 VICC 项目的临床研究优先事项，并提高 Berlin 博士的新角色将有助于将 VICC 科学转化为临床试验。 整个机构内 NCTN 试验的优先顺序。